Source: Pharamceutical Technology

Intas: Coherus divests Udenyca franchise to Intas for up to $558.4m

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals for up to $558.4m.

Read full article »
Intas's Competitors | Intas's News | Intas's Financials
Stay up-to-date with the latest news on Intas
Est. Annual Revenue
$1.0-5.0B
Est. Employees
10-50K
Binish Chudgar's photo - Managing Director of Intas

Managing Director

Binish Chudgar

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Intas